Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Express Scripts
Cerilliant
McKesson
US Department of Justice
Cantor Fitzgerald
Deloitte
Fish and Richardson
Moodys

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,241,915

« Back to Dashboard

Which drugs does patent 9,241,915 protect, and when does it expire?

Patent 9,241,915 protects OSPHENA and is included in one NDA.

This patent has twenty-five patent family members in twenty countries.
Summary for Patent: 9,241,915
Title:Method for enhancing the bioavailability of ospemifene
Abstract: This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) ##STR00001## or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.
Inventor(s): Anttila; Markku (Turku, FI)
Assignee: QuatRx Pharmaceuticals (Ann Arbor, MI)
Application Number:14/310,822
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 9,241,915

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Duchesnay OSPHENA ospemifene TABLET;ORAL 203505-001 Feb 26, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE ➤ Sign Up
Duchesnay OSPHENA ospemifene TABLET;ORAL 203505-001 Feb 26, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,241,915

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,772,353 Method for enhancing the bioavalability of ospemifene ➤ Sign Up
8,236,861 Method for enhancing the bioavailablity of ospemifene ➤ Sign Up
9,855,224 Method for enhancing the bioavailability of ospemifene ➤ Sign Up
8,470,890 Method for enhancing the bioavailability of ospemifene ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Daiichi Sankyo
Farmers Insurance
Johnson and Johnson
Chinese Patent Office
US Army
Colorcon
Argus Health
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.